Difference between revisions of "Venetoclax (Venclexta)"

Revision as of 02:32, 9 December 2014

Bcl-2 inhibitor

Abstract: Shuo Ma, John Francis Seymour, Mark C. Lanasa, Thomas J. Kipps, Jacqueline Claudia Barrientos, Matthew Steven Davids, Tanita Mason-Bright, Nikita Rudersdorf, Jianning Yang, Wijith Munasinghe, Ming Zhu, Elisa Cerri, Sari H. Enschede, Rod Humerickhouse, Andrew Warwick Roberts. ABT-199 (GDC-0199) combined with rituximab (R) in patients (pts) with relapsed/refractory (R/R) chronic lymphocytic leukemia (CLL): Interim results of a phase 1b study. J Clin Oncol 32:5s, 2014 (suppl; abstr 7013) link to abstract

Revision as of 00:28, 26 November 2014 (view source) Jwarner (talk \| contribs) m ← Older edit	Revision as of 02:32, 9 December 2014 (view source) Jwarner (talk \| contribs) m (Jwarner moved page ABT-199 (GDC-0199) to Venetoclax (ABT-199)) Newer edit →
(No difference)